Toronto, Ontario--(Newsfile Corp. - January 14, 2021) - Mindset Pharma Inc. (CSE: MSET) (“Mindset” or the “Company”), a drug discovery and development company focused on developing next generation psychedelic medicines and related technologies, is pleased to announce it has been invited to present at the Canaccord Genuity conference “New Paradigms & Treatment Approaches in Mental Health”, being held February 3-4, 2021.
Toronto, Ontario--(Newsfile Corp. - January 14, 2021) - Mindset Pharma Inc. (CSE: MSET) (“Mindset” or the “Company”), a drug discovery and development company focused on developing next generation psychedelic medicines and related technologies, is pleased to announce it has been invited to present at the Canaccord Genuity conference “New Paradigms & Treatment Approaches in Mental Health”, being held February 3-4, 2021.
James Lanthier, CEO of Mindset, commented, “Mindset is pleased to present at Canaccord Genuity’s conference. Mindset continues to make excellent progress on its next generation psilocybin drug program, which has quickly broadened to encompass a broad spectrum of patent-pending, optimized psychedelic drug candidates with a range of pharmacological and pharmacokinetic characteristics that could make them well suited for a variety of psychiatric and neurological indications and use cases. Additionally, we are making great strides towards commercializing our proprietary psilocybin manufacturing synthesis technology. We look forward to sharing the Mindset story and broadening the investor audience for Mindset and thank Canaccord Genuity for the invitation.”
For further information, along with a video overview of Mindset, please visit our website at: www.mindsetpharma.com
FOR MORE INFORMATION, PLEASE CONTACT:
James Lanthier
CEO
jlanthier@mindsetpharma.com
Jason Atkinson
VP, Corporate Development
jatkinson@mindsetpharma.com
About Mindset Pharma
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin along with its own proprietary compounds. www.mindsetpharma.com
Forward-Looking Information
This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change, unless required by law. The reader is cautioned not to place undue reliance on forward-looking information.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/72031
